Pomerantz LLP is investigating FreightCar America following the company's announcement of a major backlog cancellation involving 1,285 railcars, which led to a significant cut in its 2026 earnings forecast. The backlog removal was due to an expected customer default, causing FreightCar's stock to drop over 31%. The investigation will examine whether FreightCar and its executives engaged in securities fraud or other unlawful practices. Investors affected by this development are encouraged to contact Pomerantz LLP for potential legal action.
FreightCar America is the subject of an investor investigation. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Oct 28, 2026 04:01 WIB: of 135 priced stocks, 86 rose and 49 fell. Notable movers include EOSE at USD 1.84 (+13.58%), BA at USD 168.11 (-10.73%), and LUNR at USD 11.47 (+9.45%).
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Nokia Oyj is rated Buy due to strong demand in its Optical and IP Networks segments, driven by previous design wins and new contracts with hyperscalers. The company expects 25%-30% growth in these areas by 2027, supported by margin improvements from ...
Pomerantz LLP is investigating Concentrix Corporation and its executives for potential securities fraud following the company's lowered revenue and earnings forecasts and a significant $1.05 billion goodwill impairment. Concentrix's stock price dropp...
Icahn Enterprises L.P. announced it will present its third quarter 2026 financial results via a webcast on November 3, 2026, at 10:00 a.m. Eastern Time. The company operates across seven main sectors including Investment, Energy, Automotive, Food Pac...
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops after the European Medicines Agency (EMA) issued negative opinions on Omeros's drug narsoplimab for treating TA-TMA. The stoc...
